Back to Search
THOMAS HENSING, MD
MD
Medical Oncology Physician
NPI: 1932132743IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
036108667(IL)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
Class of 1990
Research & Publications (20)
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.
PMID 16917215·Anticancer Drugs·2006
3-trial
Clinical evaluation and staging of patients who have lung cancer.
PMID 15833404·Hematol Oncol Clin North Am·2005
6-review
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
PMID 15639724·Lung Cancer·2005
3-trial
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
PMID 12910523·Cancer·2003
3-trial
Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy.
PMID 19549915·Cancer Res·2009
8-other
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
PMID 19433684·J Clin Oncol·2009
3-trial
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
PMID 18303435·J Thorac Oncol·2008
3-trial
Prevalence of poor performance status in lung cancer patients: implications for research.
PMID 18303431·J Thorac Oncol·2008
4-observational
Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer.
PMID 18282359·Clin Lung Cancer·2008
8-other
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
PMID 17805063·J Thorac Oncol·2007
1-meta
Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.
PMID 17951232·J Natl Cancer Inst Monogr·2007
6-review
An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration.
PMID 17944147·J Support Oncol·2007
8-other
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).
PMID 17873174·Chest·2007
6-review
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
PMID 17409860·J Thorac Oncol·2006
3-trial
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
PMID 17409827·J Thorac Oncol·2006
8-other
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
PMID 16797779·Lung Cancer·2006
3-trial
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
PMID 16249215·Ann Oncol·2006
3-trial
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
PMID 15713525·Lung Cancer·2005
3-trial
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.
PMID 15570087·J Clin Oncol·2004
1-meta
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2650 RIDGE AVE
EVANSTON, IL 60201 - Phone
- (847) 570-2112
Quick Facts
- NPI
- 1932132743
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile